Optimal timing of radical cystectomy in T1 high-grade bladder cancer

Expert Review of Anticancer Therapy

Volumn 10, Issue 12, 2010, Pages 1891-1902

  Bostrm, Peter J ^a,b   Alkhateeb, Sultan ^a   Van Rhijn, Bas W G ^a   Kuk, Cynthia ^a   Zlotta, Alexandre R ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

bacillus Calmette Gu rin; BCG; bladder cancer; bladder sparing; radical cystectomy; T1 high grade; T1G3

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; EPIRUBICIN; GEMCITABINE; INTERFERON;

BCG VACCINATION; BLADDER CANCER; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CARCINOMA IN SITU; CONSERVATIVE TREATMENT; CYSTECTOMY; DRUG TREATMENT FAILURE; FIBROSIS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYDRONEPHROSIS; MEDICAL DECISION MAKING; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; T1 HIGH GRADE BLADDER CANCER; TRANSURETHRAL RESECTION; TUMOR CLASSIFICATION; TUMOR VOLUME; URINARY TRACT INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BCG VACCINE; CYSTECTOMY; HUMANS; NEOPLASM STAGING; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 78649675634     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.183     Document Type: Review

References (83)

1. Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66(6 Suppl. 1), 4-34 (2005).
2. Mostof F, Sobin L, Torloni H. Histological typing of urinary bladder tumors. In: International Classifcation of Tumors. WHO, Geneva, Switzerland (1973).
3. Eble J, Sauter G, Epstein J, Sesterhenn I. The World Health Organization Classifcation of Tumors of the Urinary System and Male Genital System. I ARC Press, Lyon, France (2004).
4. Bostrom P, van Rhijn B, Fleshner N et al. Staging and staging errors in bladder cancer. Eur. Urol. Suppl. 9(1), 2-9 (2010).
5. Fritsche H, Burger M, Svatek R et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur. Urol. 57(2), 300-309 (2010).
6. Cheng L, Neumann R, Weaver A et al. Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens. Am. J. Clin. Pathol. 113(2), 275-279 (2000).
7. Divrik R, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J. Urol. 175(5), 1641-1644 (2006).
8. Younes M, Sussman J, True L. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 66(3), 543-548 (1990).
9. Holmäng S, Hedelin H, Anderström C, Holmberg E, Johansson S. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J. Urol. 157(3), 800-803 (1997).
10. Orsola A, Trias I, Raventós C et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic signifcance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur. Urol. 48(2), 231-238 (2005).
11. Cheng L, Weaver A, Neumann R, Scherer B, Bostwick D. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 86(6), 1035-1043 (1999).
12. Cheng L, Neumann R, Weaver A, Spotts B, Bostwick D. Predicting cancer progression in patients with stage T1 bladder carcinoma. J. Clin. Oncol. 17(10), 3182-3187 (1999).
13. van der Aa M, van Leenders G, Steyerberg E et al. A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum. Pathol. 36(9), 981-986 (2005).
14. Paner G, Brown J, Lapetino S et al. Diagnostic use of antibody to smoothelin in the recognition of muscularis propria in transurethral resection of urinary bladder tumor (TURBT) specimens. Am. J. Surg Pathol. 34(6), 792-799 (2010).
15. Duchek M, Johansson R, Jahnson S et al. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-a2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur. Urol. 57(1), 25-31 (2010).
16. Orsola A, Cecchini L, Raventós C et al. Risk factors for positive fndings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR. BJU Int. 105(2), 202-207 (2010).
17. Han K, Joung J, Cho K et al. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature. J. Endourol. 22(12), 2699-2704 (2008).
18. Schwaibold H, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 97(6), 1199-1201 (2006).
19. Schips L, Augustin H, Zigeuner R et al. Is repeated transurethral resection justifed in patients with newly diagnosed superfcial bladder cancer? Urology 59(2), 220-223 (2002).
20. Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superfcial bladder cancer: is cystectomy often too early? J. Urol. 165(3), 808-810 (2001).
21. Rigaud J, Karam G, Braud G, Glemain P, Buzelin J, Bouchot O. [T1 bladder tumors: value of a second endoscopic resection]. Prog. Urol. 12(1), 27-30 (2002).
22. Herr H. The value of a second transurethral resection in evaluating patients with bladder tumors. J. Urol 162(1), 74-76 (1999).
23. Klän R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J. Urol. 146(2), 316-318 (1991).
24. Dutta S, Smith JJ, Shappell S, Coffey C, Chang S, Cookson M. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J. Urol. 166(2), 490-493 (2001).
25. Bol M, Baak J, Buhr-Wildhagen S et al Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J. Urol. 169(4), 1291-1294 (2003).
26. Herr H, Donat S. A re-staging transurethral resection predicts early progression of superfcial bladder cancer. BJU Int. 97(6), 1194-1198 (2006).
27. Divrik R, Sahin A, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specifc survival: a prospective randomised clinical trial. Eur. Urol. 58(2), 185-190 (2010).
28. Van Der Meijden A, Sylvester R, Collette L, Bono A, Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J. Urol. 164(5), 1533-1537 (2000).
29. van Rhijn B, van der Kwast T, Kakiashvili D et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int. 106(2), 206-211 (2009).
30. Lee M, Levin H, Jones J. The role of pathology review of transurethral bladder tumor resection specimens in the modern era. J. Urol. 183(3), 921-927 (2010).
31. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54(2), 303-314 (2008).
32. Jakse G, Loidl W, Seeber G, Hofstädter F. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J. Urol. 137(1), 39-43 (1987).
33. Heney N, Ahmed S, Flanagan M et al Superfcial bladder cancer: progression and recurrence. J. Urol. 130(6), 1083-1086 (1983).
34. Abel P, Hall R, Williams G. Should pT1 transitional cell cancers of the bladder still be classifed as superfcial? Br. J. Urol 62(3), 235-239 (1988).
35. Shahin O, Thalmann G, Rentsch C, Mazzucchelli L, Studer U. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guérin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J. Urol. 169(1), 96-100 (2003).
36. Mulders P, Hoekstra W, Heybroek R et al Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group. Eur. J. Cancer 30A(7), 914-917 (1994).
37. Nieder A, Brausi M, Lamm D et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 66(6 Suppl. 1), 108-125 (2005).
38. Sylvester R, van der Meijden A, Lamm D. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superfcial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168(5), 1964-1970 (2002).
39. Kulkarni G, Hakenberg O, Gschwend J et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur. Urol. 57(1), 60-70 (2010).
40. Kakiashvili DM, Van Rhijn BW, Trottier G et al. Long term follow-up of T1 high grade bladder cancer after intravesical BCG treatment. BJU Int. DOI: 10.1111/j.1464-410X.2010.09572.x (2010) (Epub ahead of print).
41. Alkhateeb S, Van Rhijn B, Finelli A et al. Nonprimary pT1 Nonmuscle invasive bladder cancer treated with bacillus Calmette-Guérin is associated with higher risk of progression compared to primary T1 tumors. J. Urol. 184(1), 81-86 (2010).
42. Zlotta A, Fleshner N, Jewett M. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can. Urol. Assoc. J. 3(6 Suppl. 4), S199-S205 (2009).
43. Hall M, Chang S, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 178(6), 2314-2330 (2007).
44. Joudi F, Smith B, O'Donnell M, Group NB-IPI. Final results from a national multicenter Phase II trial of combination bacillus Calmette- Guérin plus interferon a-2B for reducing recurrence of superfcial bladder cancer. Urol. Oncol. 24(4), 344-348 (2006).
45. Dalbagni G, Russo P, Bochner B et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J. Clin. Oncol. 24(18), 2729-2734 (2006).
46. Denzinger S, Fritsche H, Otto W, Blana A, Wieland W, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors defne feasibility of bladder-sparing approach? Eur. Urol. 53(1), 146-152 (2008).
47. Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H. Cystectomy in patients with high risk superfcial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur. Urol. 48(1), 53-59 (2005).
48. Wiesner C, Pftzenmaier J, Faldum A, Gillitzer R, Melchior S, Thüroff J. Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy. BJU Int. 95(3), 301-305 (2005).
49. Amling C, Thrasher J, Frazier H, Dodge R, Robertson J, Paulson D. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J. Urol. 151(1), 31-35 (1994).
50. Freeman J, Esrig D, Stein J et al. Radical cystectomy for high risk patients with superfcial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 76(5), 833-839 (1995).
51. Stein J, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666-675 (2001).
52. Shariat S, Karakiewicz P, Palapattu G et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J. Urol. 176(6 Pt 1), 2414-2422 (2006). (Pubitemid 44755069)
53. Madersbacher S, Hochreiter W, Burkhard F et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J. Clin. Oncol. 21(4), 690-696 (2003).
54. Hautmann R, Gschwend J, de Petriconi R, Kron M, Volkmer B. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J. Urol. 176(2), 486-492 (2006).
55. Leissner J, Ghoneim M, Abol-Enein H et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J. Urol. 171(1), 139-144 (2004).
56. Hautmann R, Volkmer B, Gust K. Quantifcation of the survival beneft of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J. Urol. 27(3), 347-351 (2009).
57. Herr H, Sogani P. Does early cystectomy improve the survival of patients with high risk superfcial bladder tumors? J. Urol. 166(4), 1296-1299 (2001). (Pubitemid 32862159)
58. Dalbagni G, Vora K, Kaag M et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur. Urol. 56(6), 903-910 (2009).
59. Weiss C, Wolze C, Engehausen D et al Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J. Clin. Oncol. 24(15), 2318-2324 (2006).
60. Harland S, Kynaston H, Grigor K et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J. Urol. 178(3 Pt 1), 807-813 (2007).
61. Lamm D, Blumenstein B, Crissman J et al Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163(4), 1124-1129 (2000).
62. Lawrentschuk N, Colombo R, Hakenberg O et al. Prevention and management of complications following radical cystectomy for bladder cancer. Eur. Urol. 57(6), 983-1001 (2010).
63. Kulkarni G, Finelli A, Fleshner N, Jewett M, Lopushinsky S, Alibhai S. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med. 4(9), e284 (2007).
64. Sylvester R, van der Meijden A, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49(3), 466-477 (2006).
65. Andius P, Johansson S, Holmäng S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 70(4), 758-762 (2007).
66. Smits G, Schaafsma E, Kiemeney L, Caris C, Debruyne F, Witjes J. Microstaging of pT1 transitional cell carcinoma of the bladder: identifcation of subgroups with distinct risks of progression. Urology 52(6), 1009-1013 (1998).
67. Divrik R, Sahin A, Altok M, Unlü N, Zorlu F. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superfcial bladder cancer. J. Urol. 178(3 Pt 1), 802-806 (2007).
68. Herr H, Dalbagni G. Defning bacillus Calmette-Guérin refractory superfcial bladder tumors. J. Urol. 169(5), 1706-1708 (2003).
69. Karl A, Stepp H, Willmann E et al. Optical coherence tomography for bladder cancer-ready as a surrogate for optical biopsy? Results of a prospective mono-centre study. Eur. J. Med. Res. 15(3), 131-134 (2010).
70. Sonn G, Jones S, Tarin T et al. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J. Urol. 182(4), 1299-1305 (2009).
71. Ehdaie B, Theodorescu D. Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis. Expert Rev. Anticancer Ther. 8(7), 1103-1110 (2008).
72. Hendricksen K, Witjes J. Current strategies for frst and second line intravesical therapy for nonmuscle invasive bladder cancer. Curr. Opin. Urol. 17(5), 352-357 (2007).
73. Addeo R, Caraglia M, Bellini S et al. Randomized Phase III trial on gemcitabine versus mytomicin in recurrent superfcial bladder cancer: evaluation of effcacy and tolerance. J. Clin. Oncol. 28(4), 543-548 (2010).
74. Jain A, Phillips R, Scally A, Lenaz G, Beer M, Puri R. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology 73(5), 1083-1086 (2009).
75. Witjes A, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J. Urol. 27(3), 319-324 (2009).
76. Liguori G, Trombetta C, Pomara G et al. Major invasive surgery for urologic cancer in octogenarians with comorbid medical conditions. Eur. Urol. 51(6), 1600-1604 (2007).
77. Boström P, Kössi J, Laato M, Nurmi M. Risk factors for mortality and morbidity related to radical cystectomy. BJU Int. 103(2), 191-196 (2008).
78. Barbieri C, Lee B, Cookson M et al. Association of procedure volume with radical cystectomy outcomes in a nationwide database. J. Urol. 178(4 Pt 1), 1418-1421 (2007).
79. Konety B, Allareddy V, Herr H. Complications after radical cystectomy: analysis of population-based data. Urology 68(1), 58-64 (2006).
80. Hautmann R, Abol-Enein H, Hafez K et al. Urinary diversion. Urology 69(Suppl. 1), 17-49 (2007).
81. Kefer J, Cherullo E, Jones J, Gong M, Campbell S. Prostate-sparing cystectomy: has Pandora's box been opened? Expert Rev. Anticancer Ther. 7(7), 1003-1014 (2007).
82. Hekal I, El-Bahnasawy M, Mosbah A, El-Assmy A, Shaaban A. Recoverability of erectile function in post-radical cystectomy patients: subjective and objective evaluations. Eur. Urol. 55(2), 275-283 (2009).
83. Puppo P, Introini C, Bertolotto F, Naselli A. Potency preserving cystectomy with intrafascial prostatectomy for high risk superfcial bladder cancer. J. Urol. 179(5), 1727-1732 (2008).